Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.
Earnings and Valuation
This table compares Bio-Rad Laboratories and OmniAb”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 3.82 | $759.90 million | $37.97 | 9.65 |
| OmniAb | $18.67 million | 38.36 | -$64.78 million | ($0.34) | -14.44 |
Bio-Rad Laboratories has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Bio-Rad Laboratories has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Bio-Rad Laboratories and OmniAb, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
Bio-Rad Laboratories currently has a consensus target price of $366.67, indicating a potential upside of 0.02%. OmniAb has a consensus target price of $11.50, indicating a potential upside of 134.22%. Given OmniAb’s stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than Bio-Rad Laboratories.
Profitability
This table compares Bio-Rad Laboratories and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 39.45% | 3.58% | 2.51% |
| OmniAb | -108.11% | -16.74% | -14.79% |
Summary
Bio-Rad Laboratories beats OmniAb on 9 of the 14 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
